PRTN3 and rheumatoid arthritis: In patients with RF/ACPA double-positive RA, abatacept retention was greater for biologic-naïve patients than in those with ≥ 1 prior biologic treatment failure (57% vs 48%) (Fig. 2B and C; combined data from patients with 1 and ≥ 2 failures of prior biologic treatment presented as further stratification would result in small patient numbers).